Hogan Lovells has advised Gilead Sciences, Inc. in entering into a technology license agreement with Xencor, Inc. for the use of XmAb® Antibody Technologies in investigational agents for HIV.
The agreement will grand Gilead Sciences access to Xencor’s Xtend™ extended half-life and Cytotoxic XmAb® Fc technologies for developing and commercializing GS-9722, Gilead’s first-in-class effector-enhanced broadly neutralizing anti-HIV antibody, which is currently in Phase 1 clinical development.
The value of the deal was not disclosed.
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma, and allergic diseases.
Gilead Sciences, Inc. is an American biotechnology company that researches, develops and commercializes drugs.
The Hogan Lovells team advising Gilead Sciences was led by Corporate partner Adam Golden (Picture) and senior associate Jeffrey Jay.
Law Firms: Hogan Lovells;
Clients: Gilead Sciences;